Hysteroscopic Findings in Ovarian Polycystic and Unexplained Infertile Women.
NCT ID: NCT05042895
Last Updated: 2023-11-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
150 participants
INTERVENTIONAL
2021-08-20
2024-12-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Therefore, if hysteroscopic examination demonstrates the endometrial pattern (echogenicity, vascularity, and thickness) in different PCO cases and correlates it to TVS and histopathology, this would recommend abstinence of endometrial curettage in some PCO patients.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methodology:
1. Study design:
A cross-sectional study.
2. Setting: Infertility out-patient clinic, Outpatient ultrasonography unit and office hysteroscopy unit of the WWoman'sHealth University Hospital Assiut University.
3. Patients:
Infertile women in the reproductive age group (18-40 years) whether 1ry or 2ry.
4. Grouping: it will include two groups of infertile women. Group A will consist of 100 PCO infertile women, while group B will consist of 50-unexplained infertility.
Sample size: the previous study could not find endometrial abnormalities hysteroscopy of women with PCOS using of rates. This study will use 100 women aiming to document more accurately the endometrial pattern in women with PCOS.
How is PCO diagnosed in this study? The diagnosis of PCO in this study will use the International evidence-based guideline for the assessment and management of PCOS 2018: The Rotterdam PCOS diagnostic criteria in adults (two of clinical or biochemical hyperandrogenism, ovulatory dysfunction, or polycystic ovaries on ultrasound) and where irregular menstrual cycles and hyperandrogenism are present, highlight that ultrasound is not necessary for diagnosis.
International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome published in 2018 changed the ultrasound criteria from ≥12 to ≥20 antral follicles in an ovary to diagnose PCOS.
PCOS diagnosis is based on oligo-anovulation (OA), biochemical or clinical hyperandrogenism (HA), and polycystic ovary morphology (PCOM) on ultrasound extending across the original 1990 National Institutes of Health (NIH) criteria (OA and HA).
The 2003 Rotterdam criteria (any two of OA, HA, and PCOM) , and the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society criteria (HA and OA or PCOM or both) .
The Rotterdam criteria are now widely accepted and generate four possible diagnostic PCOS phenotypes in adult women: (A) OA + HA + PCOM, (B) OA + HA, (C) HA + PCOM, and (D) OA + PCOM . The Rotterdam criteria are recommended and endorsed by the 2018 international PCOS evidence-based guideline, which was co-developed based on unprecedented evidence synthesis and best practice methods, by world-leading multidisciplinary clinicians and researchers across 37 societies from 71 countries, with consumer engagement .
Within eight years of menarche, both hyperandrogenism and ovulatory dysfunction are required, with ultrasound not recommended. Ultrasound criteria are tightened with advancing technology. Anti-Müllerian hormone levels are not yet adequate for diagnosis
Data collection:
Demographic data will be collected age, weight, BMI (weight \[kg\] divided by height in meters squared \[m2\]), obstetrics and gynecology history (duration of infertility and variability of menstrual cycles), and medications metformin, CC, and tamoxifen. .
TVS findings:
1. International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome published in 2018 Ovarian volume \> 10 cm and ≥20antral follicles in an ovary
2. Presence of ovulation or not,
3. endometrial thickness and echognicity,
4. anyadenxal or uterine abnormalities. Doppler U/S. whenever indicated e.g, endometrial mass lesion Hormonal profile assessment: Baseline day 3 serum FSH, LH, Prolactin, TSH. Pre ovulatory urinary LH will be done in all cases.
Office hysteroscopic examination (2.6 telescopes and 3.2 mm outer sheath): assessment of the following:
* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.
* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.
* Darwish hysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.
Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.
Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle.
5. Ethical considerations:
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PCO women
Group A will consist of 100 PCO infertile women
Group A
Office diagnostic hysteroscopy for assessment of the following:
* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.
* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.
* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.
Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.
Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle.
unexplained infertile cases
group B will consist of 50-unexplained infertility.
Group B
Office diagnostic hysteroscopy for assessment of the following:
* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.
* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.
* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.
Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.
Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group A
Office diagnostic hysteroscopy for assessment of the following:
* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.
* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.
* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.
Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.
Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle.
Group B
Office diagnostic hysteroscopy for assessment of the following:
* cervical canal: arborvitae, mucous, any abnormal pathology like a polyp.
* Endometrium cavity: vascularity, thickness, color, gland openings, any abnormal pathology.
* Darwishhysterscopic triad: shape, caliber, depth, abnormal pathology, flow patency, bubble flow patency, and peristalsis.
Endometrial sample by a Novak's curette Histopathologic assessment: will be sent for the routine out-patient Pathology lab to comment on the endometrial pattern and abnormalities.
Physical and laboratory examinations follicle-stimulating hormone \[FSH\], LH, thyroid-stimulating hormone \[TSH\], prolactin, and pre ovulatory LH LH levels of the patients will be measured on day 3 of the menstrual cycle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Infertility: 1ry or 2ry.
3. No contraindication for hysteroscopy or histopathology. e.g severe bleeding cervical stenosis.
4. Postmenstrual.
Exclusion Criteria
* Non infertility.
* Adolescents and virgins.
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Woman's Health University Hospital, Egypt
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Professor Atef Darwish
Professor of Obstetrics and Gynecology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Atef mm Darwish
Role: STUDY_DIRECTOR
Woman's Health University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Woman's Health University Hospital
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCO
Identifier Type: -
Identifier Source: org_study_id